Looking to the future: biomarkers in the management of pancreatic adenocarcinoma.
The incidence and mortality of pancreas cancer converge. There has been little advancement in the treatment of pancreas cancer since the acceptance of gemcitabine as the standard therapy. Unfortunately, the efficacy of gemcitabine is dismal. While there is much discussion for the development of biomarkers to help direct therapy in this area, there is little action to move them into clinical practice. Herein, we review potential pancreatic cancer biomarkers and discuss the limitations in their implementation.
Department of Oncology, Cross Cancer Institute, School of Cancer, Imaging and Engineering Sciences, Faculty of Medicine and Dentistry, University of Alberta, 11560 University Avenue, Edmonton, Alberta, T6G 1Z2, Canada.
Jennifer L
JL
Spratlin
Karen E
KE
Mulder
D000230:Adenocarcinoma / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D006801:Humans; D017063:Outcome Assessment, Health Care / Q000379:methods; D010190:Pancreatic Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
D000964:Antimetabolites, Antineoplastic; D014408:Biomarkers, Tumor